655 related articles for article (PubMed ID: 28441895)
21. Intravenous ketamine for treatment-resistant major depressive disorder.
Covvey JR; Crawford AN; Lowe DK
Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature.
Banov MD; Young JR; Dunn T; Szabo ST
CNS Spectr; 2020 Jun; 25(3):331-342. PubMed ID: 31339086
[TBL] [Abstract][Full Text] [Related]
23. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.
Niciu MJ; Shovestul BJ; Jaso BA; Farmer C; Luckenbaugh DA; Brutsche NE; Park LT; Ballard ED; Zarate CA
J Affect Disord; 2018 May; 232():310-315. PubMed ID: 29501990
[TBL] [Abstract][Full Text] [Related]
24. Ketamine treatment for refractory anxiety: A systematic review.
Tully JL; Dahlén AD; Haggarty CJ; Schiöth HB; Brooks S
Br J Clin Pharmacol; 2022 Oct; 88(10):4412-4426. PubMed ID: 35510346
[TBL] [Abstract][Full Text] [Related]
25. Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale.
Truppman Lattie D; Nehoff H; Neehoff S; Gray A; Glue P
J Psychopharmacol; 2021 Feb; 35(2):137-141. PubMed ID: 32900266
[TBL] [Abstract][Full Text] [Related]
26. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.
Lee JH; Dunner DL
Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265
[TBL] [Abstract][Full Text] [Related]
27. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
28. Ketamine for depression.
Jelen LA; Stone JM
Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
[TBL] [Abstract][Full Text] [Related]
29. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
30. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
[TBL] [Abstract][Full Text] [Related]
31. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Nugent AC; Wills KE; Gilbert JR; Zarate CA
Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
[TBL] [Abstract][Full Text] [Related]
32. Suicidality in treatment resistant depression: perspective for ketamine use.
Jakuszkowiak-Wojten K; Gałuszko-Węgielnik M; Wilkowska A; Słupski J; Włodarczyk A; Górska N; Szarmach J; Szałach ŁP; Wiglusz MS; Krysta K; Cubała WJ
Psychiatr Danub; 2019 Sep; 31(Suppl 3):258-260. PubMed ID: 31488737
[TBL] [Abstract][Full Text] [Related]
33. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
[TBL] [Abstract][Full Text] [Related]
34. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
35. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review.
du Jardin KG; Müller HK; Elfving B; Dale E; Wegener G; Sanchez C
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():27-38. PubMed ID: 27262695
[TBL] [Abstract][Full Text] [Related]
36. Targeting of NMDA receptors in the treatment of major depression.
Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
[TBL] [Abstract][Full Text] [Related]
37. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
38. Creating more effective antidepressants: clues from the clinic.
Rasmussen K
Drug Discov Today; 2006 Jul; 11(13-14):623-31. PubMed ID: 16793531
[TBL] [Abstract][Full Text] [Related]
39. Ketamine as an alternative treatment for treatment-resistant depression.
Dowben JS; Grant JS; Keltner NL
Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
[No Abstract] [Full Text] [Related]
40. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]